Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma

An overview

Monica Marra, Ignazio M. Sordelli, Angela Lombardi, Monica Lamberti, Luciano Tarantino, Aldo Giudice, Paola Stiuso, Alberto Abbruzzese, Rossella Sperlongano, Marina Accardo, Massimo Agresti, Michele Caraglia, Pasquale Sperlongano

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with multiple genetic aberrations. Several molecular pathways involved in the regulation of proliferation and cell death are implicated in the hepatocarcinogenesis. The major etiological factors for HCC are both hepatitis B virus (HBV) and hepatitis C virus infection (HCV).Continuous oxidative stress, which results from the generation of reactive oxygen species (ROS) by environmental factors or cellular mitochondrial dysfunction, has recently been associated with hepatocarcinogenesis. On the other hand, a distinctive pathological hallmark of HCC is a dramatic down-regulation of oxido-reductive enzymes that constitute the most important free radical scavenger systems represented by catalase, superoxide dismutase and glutathione peroxidase.The multikinase inhibitor sorafenib represents the most promising target agent that has undergone extensive investigation up to phase III clinical trials in patients with advanced HCC. The combination with other target-based agents could potentiate the clinical benefits obtained by sorafenib alone. In fact, a phase II multicenter study has demonstrated that the combination between sorafenib and octreotide LAR (So.LAR protocol) was active and well tolerated in advanced HCC patients.The detection of molecular factors predictive of response to anti-cancer agents such as sorafenib and the identification of mechanisms of resistance to anti-cancer agents may probably represent the direction to improve the treatment of HCC.

Original languageEnglish
Article number171
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - Oct 10 2011

Fingerprint

Oxidative stress
Biomarkers
Hepatocellular Carcinoma
Oxidative Stress
Viruses
Free Radical Scavengers
Octreotide
Cell death
Glutathione Peroxidase
Aberrations
Catalase
Superoxide Dismutase
Tumors
Reactive Oxygen Species
Neoplasms
Phase III Clinical Trials
Virus Diseases
Hepatitis B virus
Hepacivirus
Multicenter Studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma : An overview. / Marra, Monica; Sordelli, Ignazio M.; Lombardi, Angela; Lamberti, Monica; Tarantino, Luciano; Giudice, Aldo; Stiuso, Paola; Abbruzzese, Alberto; Sperlongano, Rossella; Accardo, Marina; Agresti, Massimo; Caraglia, Michele; Sperlongano, Pasquale.

In: Journal of Translational Medicine, Vol. 9, No. 1, 171, 10.10.2011.

Research output: Contribution to journalArticle

Marra, M, Sordelli, IM, Lombardi, A, Lamberti, M, Tarantino, L, Giudice, A, Stiuso, P, Abbruzzese, A, Sperlongano, R, Accardo, M, Agresti, M, Caraglia, M & Sperlongano, P 2011, 'Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview', Journal of Translational Medicine, vol. 9, no. 1, 171. https://doi.org/10.1186/1479-5876-9-171
Marra, Monica ; Sordelli, Ignazio M. ; Lombardi, Angela ; Lamberti, Monica ; Tarantino, Luciano ; Giudice, Aldo ; Stiuso, Paola ; Abbruzzese, Alberto ; Sperlongano, Rossella ; Accardo, Marina ; Agresti, Massimo ; Caraglia, Michele ; Sperlongano, Pasquale. / Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma : An overview. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{cdb0e10c16674e6992c45a4e39f3ad47,
title = "Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview",
abstract = "Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with multiple genetic aberrations. Several molecular pathways involved in the regulation of proliferation and cell death are implicated in the hepatocarcinogenesis. The major etiological factors for HCC are both hepatitis B virus (HBV) and hepatitis C virus infection (HCV).Continuous oxidative stress, which results from the generation of reactive oxygen species (ROS) by environmental factors or cellular mitochondrial dysfunction, has recently been associated with hepatocarcinogenesis. On the other hand, a distinctive pathological hallmark of HCC is a dramatic down-regulation of oxido-reductive enzymes that constitute the most important free radical scavenger systems represented by catalase, superoxide dismutase and glutathione peroxidase.The multikinase inhibitor sorafenib represents the most promising target agent that has undergone extensive investigation up to phase III clinical trials in patients with advanced HCC. The combination with other target-based agents could potentiate the clinical benefits obtained by sorafenib alone. In fact, a phase II multicenter study has demonstrated that the combination between sorafenib and octreotide LAR (So.LAR protocol) was active and well tolerated in advanced HCC patients.The detection of molecular factors predictive of response to anti-cancer agents such as sorafenib and the identification of mechanisms of resistance to anti-cancer agents may probably represent the direction to improve the treatment of HCC.",
author = "Monica Marra and Sordelli, {Ignazio M.} and Angela Lombardi and Monica Lamberti and Luciano Tarantino and Aldo Giudice and Paola Stiuso and Alberto Abbruzzese and Rossella Sperlongano and Marina Accardo and Massimo Agresti and Michele Caraglia and Pasquale Sperlongano",
year = "2011",
month = "10",
day = "10",
doi = "10.1186/1479-5876-9-171",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma

T2 - An overview

AU - Marra, Monica

AU - Sordelli, Ignazio M.

AU - Lombardi, Angela

AU - Lamberti, Monica

AU - Tarantino, Luciano

AU - Giudice, Aldo

AU - Stiuso, Paola

AU - Abbruzzese, Alberto

AU - Sperlongano, Rossella

AU - Accardo, Marina

AU - Agresti, Massimo

AU - Caraglia, Michele

AU - Sperlongano, Pasquale

PY - 2011/10/10

Y1 - 2011/10/10

N2 - Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with multiple genetic aberrations. Several molecular pathways involved in the regulation of proliferation and cell death are implicated in the hepatocarcinogenesis. The major etiological factors for HCC are both hepatitis B virus (HBV) and hepatitis C virus infection (HCV).Continuous oxidative stress, which results from the generation of reactive oxygen species (ROS) by environmental factors or cellular mitochondrial dysfunction, has recently been associated with hepatocarcinogenesis. On the other hand, a distinctive pathological hallmark of HCC is a dramatic down-regulation of oxido-reductive enzymes that constitute the most important free radical scavenger systems represented by catalase, superoxide dismutase and glutathione peroxidase.The multikinase inhibitor sorafenib represents the most promising target agent that has undergone extensive investigation up to phase III clinical trials in patients with advanced HCC. The combination with other target-based agents could potentiate the clinical benefits obtained by sorafenib alone. In fact, a phase II multicenter study has demonstrated that the combination between sorafenib and octreotide LAR (So.LAR protocol) was active and well tolerated in advanced HCC patients.The detection of molecular factors predictive of response to anti-cancer agents such as sorafenib and the identification of mechanisms of resistance to anti-cancer agents may probably represent the direction to improve the treatment of HCC.

AB - Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with multiple genetic aberrations. Several molecular pathways involved in the regulation of proliferation and cell death are implicated in the hepatocarcinogenesis. The major etiological factors for HCC are both hepatitis B virus (HBV) and hepatitis C virus infection (HCV).Continuous oxidative stress, which results from the generation of reactive oxygen species (ROS) by environmental factors or cellular mitochondrial dysfunction, has recently been associated with hepatocarcinogenesis. On the other hand, a distinctive pathological hallmark of HCC is a dramatic down-regulation of oxido-reductive enzymes that constitute the most important free radical scavenger systems represented by catalase, superoxide dismutase and glutathione peroxidase.The multikinase inhibitor sorafenib represents the most promising target agent that has undergone extensive investigation up to phase III clinical trials in patients with advanced HCC. The combination with other target-based agents could potentiate the clinical benefits obtained by sorafenib alone. In fact, a phase II multicenter study has demonstrated that the combination between sorafenib and octreotide LAR (So.LAR protocol) was active and well tolerated in advanced HCC patients.The detection of molecular factors predictive of response to anti-cancer agents such as sorafenib and the identification of mechanisms of resistance to anti-cancer agents may probably represent the direction to improve the treatment of HCC.

UR - http://www.scopus.com/inward/record.url?scp=80053608796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053608796&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-171

DO - 10.1186/1479-5876-9-171

M3 - Article

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 171

ER -